2:56 PM
 | 
Jan 24, 2018
 |  BC Extra  |  Financial News

Follow-on roundup

At least six companies priced follow-ons, raising more than $600 million total.

Rare disease company Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) raised $250 million on Tuesday through the sale of 4.4 million shares at $57 in a bumped-up follow-on underwritten by J.P. Morgan, BofA Merrill Lynch, Goldman Sachs and Cowen. The price is a 7% premium to Ultragenyx's close of $53.39 on Monday, when it proposed after market hours to raise $175 million.

The company gained a combined $8.98 (18%) on Monday and Tuesday as the market digested news of multi-billion life science deals, including the takeouts of gene therapy...

Read the full 479 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >